NRXP

NRx Pharmaceuticals, Inc. (NRXP) | Rumor.io

NRx Pharmaceuticals

NRXP

Attention (50-day avg)0%

Attention rank (50-day avg)#1,114

Bullish sentiment (50-day avg)93%

Price to earnings ratio0.36

Market capitalization124.3M

Earnings per share-0.51

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-28.6M

Social

What share of all stock conversation is about NRXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Sep 16

NRx Pharmaceuticals (NRXP) has reported an update from the FDA, revising a major amendment to a minor amendment for preservative-free ketamine.
The FDA's competency has been questioned, with concerns raised about the timeliness and ease of tasks, including the approval process for NRXP's ketamine treatment.
NRXP has the potential to be profitable next year, with the company's valuation expected to realign favorably as the market adjusts to macroeconomic forces, including the growing challenge to the US dollar's dominance and increasing efforts to repatriate gold reserves.

Generated by AI

Sentiment

Of the messages about NRXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.51% -6.49	88.94% -1.89	84.71% -3.9
Bearish	—	6.49% +6.49	11.06% +1.89	15.29% +3.9

Bullish· Aug 7

$NRXP has already surpassed the EMA 200 and 400, indicating a strong and positive outlook.
The company is expected to receive approval, which will lead to a massive gain and potentially a price of $8-$10 in the short term.
According to analysts polled by S&P Global, NRx Pharmaceuticals has a consensus rating of "Strong Buy" and an average price target of $42, with a potential 1,076.47% increase in stock price.

Bearish· Jun 3

The company's recent stock offering may be a prudent use of its currency, but it may also be perceived as a disappointment, especially considering the company's need for cash to grow.
The stock drop may be attributed to the company's decision to issue a secondary stock offering, which could be seen as a way to shake out weak hands and allow another group to cover before good news is announced.
The company's management may be perceived as disconnected from shareholders, as evidenced by their decision to issue a secondary stock offering despite previous talk of investigating naked shorts and manipulation.

Generated by AI

Topics

Of the messages about NRXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	87.5%	98.43%	78.93%
Technical Analysis	0%	0%	0.79%	7.96%
Controversies	100%	12.5%	0.79%	5.04%
Analysts	0%	0%	0%	7.26%
Earnings	0%	0%	0%	0.8%
Macro	0%	0%	0%	0%

Announcements· May 28

NRx Pharmaceuticals' strategic partner Emobot has presented late-breaking clinical validation of the EMOCARE Depression Thermometer at ASCP 2026, showing 90% within-person concordance with clinician MADRS.
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior.
The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.

Controversies· Jan 20

NRx Pharmaceuticals, Inc. (NRXP) is facing multiple class-action lawsuits alleging the company made materially false statements about the potential for its EUA application to be approved based on RCT data only.
The lawsuits claim NRXP misrepresented the truth and caused damage, but NRXP insiders sold shares at a price close to the launchpad, and the private placement took place at $11, a price very close to the pre-EUA price.
The FDA would not have accepted re-submitted applications if they didn't feel the content was significantly different, which means the class-action lawsuit claims are likely false as no new data was introduced, just new analysis.

Technical Analysis· Jul 29

$NRXP has resistance near $1.06, $1.13, and $1.20, with support near previous levels.
A bullish pennant flag is forming in $NRXP, with a potential breakout above $1.
$NRXP is oversold, with an RSI of 24, and is expected to bounce back, with potential targets at $1 and $1.05.

Generated by AI

Community

Of the messages about NRXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	45.28%	40.6%	57.38%
Newcomers	0%	54.72%	59.4%	42.62%

Regulars· Sep 15

The FDA has reclassified NRx Pharmaceuticals' (NRXP) ANDA amendment to a minor amendment, moving the GDUFA goal date to November 10, 2026, which could indicate a faster approval process for the company's preservative-free ketamine product.
Dr. Javitt, an FDA expert, has mentioned that the company's ANDA could be approved in mid-October, but this has not been officially announced to the SEC, and no timeline has been met so far, leaving uncertainty about the approval process.
The company's stock price has experienced unusual and highly bullish price action, with a 45-minute increase in volume and price, suggesting a potential catalyst for the stock's movement, although the reasons behind this action are unclear.

Newcomers· Sep 16

New traders are focusing on building a long-term portfolio with a mix of conservative and aggressive investments.
Some newcomers are taking a cautious approach, investing in money markets until market conditions improve.
Small business owners and individuals, like a 50-year-old female, are entering the market with a small stake, such as 1000 shares of NRXP.

Generated by AI

Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic Drugs User Fee Act (GDUFA) Goal Date to November 10, 2026. WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has received a written communi

14d agoYahoo Finance

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP)

KETAFREE can turn NRx Pharmaceuticals’ ketamine opportunity into a commercial business, provided FDA approval leads to a successful launch. More on NRXP stock.

15d agoSeeking Alpha

NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum

18d agoInvesting.com

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's headquarters in Boston ahead of deployment in HOPE's Florida clinicsThe Zeta TMS Robotic System's AI-driven software adjusts the TMS coil in real time with submillimeter precision, building on the Zeta TMS Navigation System HOPE implemented earlier this summerDeployment supports SPARC-TMS, NRx's trial

19d agoYahoo Finance

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026. Moody Capital Solutions 2026 Disruptive Growth & Life Sciences ConferenceCompany PresentationPresenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer of NRx PharmaceuticalsL

22d agoYahoo Finance

Also Discussed

Investors talking about NRXP also mention

#	Name	Attention
1	BeyondSpring Inc.BYSI	0%0
2	Longeveron Inc. Class A Common StockLGVN	0%0
3	Pasithea Therapeutics Corp.KTTA	0%0
4	Biofrontera Inc.BFRI	0%0
5	iSpecimen Inc.ISPC	0%0
6	NanoVibronix, Inc.NAOV	0%0
7	Flora Growth Corp.FLGC	0%new
8	MediaCo Holding Inc. Class A Common StockMDIA	0%0
9	CEMI - Chembio Diagnostics, Inc.	——
10	Society Pass IncorporatedSOPA	0%0

NRx Pharmaceuticals, Inc.

Healthcare
Biotechnology

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. The company also works on adjacent neuropsychiatric and respiratory care initiatives through its broader portfolio and operating segments. NRx Pharmaceuticals, Inc. serves a specialized role in psychiatry by targeting high-unmet-need conditions where conventional treatment options may be limited or insufficient. Headquartered in Wilmington, Delaware, it operates as a focused developer of novel therapeutics for complex mental health and neurological indications.

Website

Location

1201 N. Market Street

Wilmington, DE, 19801

United States

Social

What share of all stock conversation is about NRXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Sep 16

NRx Pharmaceuticals (NRXP) has reported an update from the FDA, revising a major amendment to a minor amendment for preservative-free ketamine.
The FDA's competency has been questioned, with concerns raised about the timeliness and ease of tasks, including the approval process for NRXP's ketamine treatment.
NRXP has the potential to be profitable next year, with the company's valuation expected to realign favorably as the market adjusts to macroeconomic forces, including the growing challenge to the US dollar's dominance and increasing efforts to repatriate gold reserves.

Generated by AI

Sentiment

Of the messages about NRXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.51% -6.49	88.94% -1.89	84.71% -3.9
Bearish	—	6.49% +6.49	11.06% +1.89	15.29% +3.9

Bullish· Aug 7

$NRXP has already surpassed the EMA 200 and 400, indicating a strong and positive outlook.
The company is expected to receive approval, which will lead to a massive gain and potentially a price of $8-$10 in the short term.
According to analysts polled by S&P Global, NRx Pharmaceuticals has a consensus rating of "Strong Buy" and an average price target of $42, with a potential 1,076.47% increase in stock price.

Bearish· Jun 3

The company's recent stock offering may be a prudent use of its currency, but it may also be perceived as a disappointment, especially considering the company's need for cash to grow.
The stock drop may be attributed to the company's decision to issue a secondary stock offering, which could be seen as a way to shake out weak hands and allow another group to cover before good news is announced.
The company's management may be perceived as disconnected from shareholders, as evidenced by their decision to issue a secondary stock offering despite previous talk of investigating naked shorts and manipulation.

Generated by AI

Topics

Of the messages about NRXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	87.5%	98.43%	78.93%
Technical Analysis	0%	0%	0.79%	7.96%
Controversies	100%	12.5%	0.79%	5.04%
Analysts	0%	0%	0%	7.26%
Earnings	0%	0%	0%	0.8%
Macro	0%	0%	0%	0%

Announcements· May 28

NRx Pharmaceuticals' strategic partner Emobot has presented late-breaking clinical validation of the EMOCARE Depression Thermometer at ASCP 2026, showing 90% within-person concordance with clinician MADRS.
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior.
The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.

Controversies· Jan 20

NRx Pharmaceuticals, Inc. (NRXP) is facing multiple class-action lawsuits alleging the company made materially false statements about the potential for its EUA application to be approved based on RCT data only.
The lawsuits claim NRXP misrepresented the truth and caused damage, but NRXP insiders sold shares at a price close to the launchpad, and the private placement took place at $11, a price very close to the pre-EUA price.
The FDA would not have accepted re-submitted applications if they didn't feel the content was significantly different, which means the class-action lawsuit claims are likely false as no new data was introduced, just new analysis.

Technical Analysis· Jul 29

$NRXP has resistance near $1.06, $1.13, and $1.20, with support near previous levels.
A bullish pennant flag is forming in $NRXP, with a potential breakout above $1.
$NRXP is oversold, with an RSI of 24, and is expected to bounce back, with potential targets at $1 and $1.05.

Generated by AI

Community

Of the messages about NRXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	45.28%	40.6%	57.38%
Newcomers	0%	54.72%	59.4%	42.62%

Regulars· Sep 15

The FDA has reclassified NRx Pharmaceuticals' (NRXP) ANDA amendment to a minor amendment, moving the GDUFA goal date to November 10, 2026, which could indicate a faster approval process for the company's preservative-free ketamine product.
Dr. Javitt, an FDA expert, has mentioned that the company's ANDA could be approved in mid-October, but this has not been officially announced to the SEC, and no timeline has been met so far, leaving uncertainty about the approval process.
The company's stock price has experienced unusual and highly bullish price action, with a 45-minute increase in volume and price, suggesting a potential catalyst for the stock's movement, although the reasons behind this action are unclear.

Newcomers· Sep 16

New traders are focusing on building a long-term portfolio with a mix of conservative and aggressive investments.
Some newcomers are taking a cautious approach, investing in money markets until market conditions improve.
Small business owners and individuals, like a 50-year-old female, are entering the market with a small stake, such as 1000 shares of NRXP.

Generated by AI

NRx Pharmaceuticals

Social

Sep 16

Bullish· Aug 7

Bearish· Jun 3

Announcements· May 28

Controversies· Jan 20

Technical Analysis· Jul 29

Regulars· Sep 15

Newcomers· Sep 16

NRx Pharmaceuticals’ ketamine ANDA amendment reclassified

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP)

NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

Also Discussed

NRx Pharmaceuticals, Inc.

Company Information

Location

NRx Pharmaceuticals’ ketamine ANDA amendment reclassified

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry (NASDAQ:NRXP)

NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

Also Discussed

Social

Sep 16

Bullish· Aug 7

Bearish· Jun 3

Announcements· May 28

Controversies· Jan 20

Technical Analysis· Jul 29

Regulars· Sep 15

Newcomers· Sep 16